Iingxelo zeeNkcazo zichaphazela njani abantu abane-Cancer Cancer?
Statin Drugs kunye ne-Cancer Cancer
Kusenokwenzeka ukuba uve ukuba izidakamizwa ze-statin zinokuphucula umhlaza womphunga wamaphaphu, uncedise unyango okanye umngcipheko wesifo somhlaza wamaphaphu. Phakathi kwayo yonke le ngqungquthela, izifundo zibonisa ntoni? Ngaba bathetha ngokuthintela umdlavuza wamaphaphu ngaphambi kokuba uqale, okanye unyango lomhlaza wamaphaphu emva kokuba sele ukhona? Ngaba uhlobo lomhlaza womphunga kwaye luba lubaphi naziphi ezinye unyango ozilisebenzisayo?
Ngamanye amaxesha izazinzulu ziyamangaliswa xa unyango lwemoya enye lubonakala lunceda imeko engalinganiyo. Izitatimende zee-Statins zingaba nye kwezi zonyango. La mayeza anciphisa i-cholesterol phakathi kwezinye iindawo zezi ezinye izidakamizwa eziqhelekileyo eziqhelekileyo emhlabeni jikelele. Abaphandi baye bathatha umdla ngakumbi kula mayeza kwiminyaka yamuva emva kokubona ukulungelelaniswa phakathi kokusetyenziswa kwezi nkunkuma kunye nokuphila komhlaza.
Ziziphi iiNkcazo?
Iitatimins zididi lweemithi ezibizwa ngokuba yi-HMG-CoA iyanciphisa i-inhibitors. Nangona uluntu luvame ukujonga leziyobisi ngokuthi "i-cholesterol". Ukongeza ekunciphiseni i-cholesterol, ezi ziyeza zizinzisa iiplati kwiimitha ze-coronary , zinciphisa ubukhulu beplate kwiimitha ze-coronary, kwaye zinciphisa ukubunjwa kwegazi kwiimitha ze-coronary. Ngaloo ndlela, ama-statins anganciphisa ubungozi benhliziyo nangona i-cholesterol evamile.
Ngakolunye uhlangothi lwe-equation, unyango lwe-cholesterol ephakamileyo yedwa - ngaphandle kokuba lwenza umehluko kwimpilo nokuphila-akuyiyo injongo yonyango lomzimba.
Njani i-Statins ifuthe ingozi yeCcercer?
Izifundo zezilwanyana kunye nezifundo zeeseli (ukujonga iiseli zomhlaza ezikhulile kwisitya) ziye zaphakamisa ukuba izitho zinezixhobo zokulwa nomhlaza.
Kucingelwa ukuba banokubamba ukukhula kweeseli, ukuhlasela, kunye nokwenzeka kwamaseli omhlaza ukusabalalisa (i-metastasize.)
Ngokweqela elinye labaphenyi, ama-statins aphezulu kakhulu (i-fat-loving) iya kuba yinkqubela phambili. Iimpawu ezininzi ze-lipophilic ziquka i-Lipitor (atorvastatin), iZocor (simvastatin) kunye neMevacor (lovastatin). I-lipophilic encinci (i-hydrophilic okanye "i-water-loving") i-statins iquka iPravachol (pravastatin), iCrestor (rosuvastatin) kunye ne-Lescol (i-fluvastatin).
I-Statins kunye neLung Cancer Survival
Uphononongo olutshanje lubonisa ukuba abantu abathabatha izidakamizwa ze-statin ngaphambi okanye emva kokuxilongwa komhlaza wamaphaphu banokungena kwezinga lokusinda.
Kule sifundo malunga nabantu abayi-14 000 abanomdlavuza wamaphaphu e-UK phakathi ko-1998 no-2009, abantu abasebenzisa izidakamizwa ze-statin phambi kokuxilongwa kwabo babenokunciphisa inani leepesenti ezili-12 ekufeni kwabantu abachaphazeleka ngumhlaza.
Kulabo basebenzise izidakamizwa ze-statin emva kokuxilongwa kwabo , kwaye bahlala ubuncinane ubuncinane kweenyanga ezili-6, kukho ukunciphisa okwenkcenkceshe okuthe ngqo kwimizimba yokufa komhlaza wamaphaphu ama-11 ekhulwini. Kwabo bazalise imimiselo yabo ubuncinane ngamaxesha angama-12 (basebenzisa unyaka okanye ngaphezulu,) kukho ukunciphisa amanqaku okufa komhlaza wamapayipi ama- 19 ekhulwini.
Olu phofu lubhekiselele kubantu abanomdlavuza wesifo somhlaza wamangqamuzana kunye nomdlavuza omncinci wamangqamuzana wesifo somdlavuza kwaye uguqulela kwizigulane ze-cancer ezingama-3,638 ezinokunciphisa ukufa komdlavuza othile wamaphaphu. Ukuba la manani afanele afake isicelo kubantu abaqhelekileyo abanomdlavuza wamaphaphu, oku akuyi kuba yinani elincinci, kuba kulindeleke ukuba abantu abayi-158.040 baya kufa ngomdlavuza wamaphaphu ngo-2015 e-United States kuphela. Njengoko kuthelekiswa ngokukhawuleza, abantu abayi-3,000 bafa emlilweni ochaphazelekayo ekhaya eMelika ngamnye ngonyaka.
Kubalulekile ukuba uqaphele ukuba olu phando lusekuqaleni , kwaye asinakuqiniseka ukuba izidakamizwa ze-statin ngokwayo zibangela ukunciphisa ekufeni .
Ngokomzekelo, kukho enye into (enye inguquko) kubantu abasebenzisa izidakamizwa ze-statin endaweni edibeneyo kunye nokuphila okuphuculweyo.
I-Statins kunye neLung Cancer Mortality
Ukuphononongwa kweengxelo ezipapashwe ngo-Apreli 2015 (izifundo ezingama-41) zijonge umphumo weemimiselo ngokufa komdlavuza jikelele, kubonakala zixhasa inkxaso yokuba i-statins inokuchaphazela ukusinda komhlaza. Ezi zifundo, ezibandakanya abantu abangaphezu kwezigidi zabantu, zibonisa ukuba ukusetyenziswa kweemimiselo emva kokuxilongwa komhlaza kunxulumene nokunciphisa i-19 ekhulwini kwizinto ezibangelwa ukufa kunye nokunciphisa ama-23 ekhulwini lokufa komdlavuza. Isiphetho sabaphandi abajonge ezi zifundo kukuba "ukusetyenziswa kweempawu zombini ngaphambi nangemva kokuxilongwa kuyinzuzo ngokuqhubekayo nokuphila komhlaza othile." Kubalulekile ukuba uqaphele, nangona kunjalo, ukuba umhlaza wemiphunga nje ushiya emva kwezinye zezifundo, kunye neziphumo ezininzi ekukhangela umdlavuza webele, umhlaza omnxeba kunye nomhlaza wesibeletho.
Impembelelo yeeNkcazo kwiNyango yeMhlaza yeLung
Akukho nto eyaziwayo malunga nendlela iimpawu zithintela ngayo unyango lomntu ngamnye ngomhlaza, kodwa isifundo esincinci esisodwa safumanisa ukuba ukongeza i-statin kumachiza afana neTarceva kubangele ukuphuculwa ngokuphawulekayo kwindlela yokuphila engenakho ukuqhubekayo kubantu abanomdlavuza omncinci wesifo somnxeba. ukuguqulwa kwe-KRAS. Eli nqaku lixubusha ukuvavanya ukuguquka kwemfuza kubantu abanomdlavuza wamaphaphu .
Ngokwesiko, abantu abavavanya i-positive KRAS mutation abaphenduli kakuhle nemithi ebizwa ngokuba yi-epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs ). Amachiza kulolu hlobo (imithi ejoliswe kuyo) esetyenziswa kumdlavuza wamaphaphu kuquka iTarceva (erlotinib) kunye ne-Iressa (gefitinib). Kubantu abanesigaba se-3B kunye nesigaba se-4 esingekho esincinci somhlaza wesifo somhlaza wamaphaphu esifanelekileyo sokuguquguquka kwe-KRAS, ukongezwa kwesimo semimiselo kuphindwe kabini ubude bokusinda kwenkululeko.
Izifundo zangaphambili kumaseli omhlaza womphunga wabantu zifumanise ukuba ukongeza iseli somhlaza wesifo se-pulin. Ngokucacileyo, kucingelwa ukuba i-statin iphumela ekunciphiseni kwi-isoprenoids enefuthe kwi-RAS-ngenxa yoko ibonakala kwindlela ebonakalayo kumaseli omhlaza wemiphunga kunye noguquko lwe-KRAS.
Iimpawu zeNkcazo kunye neLung Cancer Prevention
Nangona isifundo esincinci esincinci asifumananga isiqhagamshelo phakathi koomzimba kunye nokukhusela umdlavuza wamaphaphu, uphando olutshanje lwaseTaiwan lubonise inxaxheba ebalulekileyo, ubuncinane kubasetyhini, ngakumbi abo banezinye izifo zokuphefumula ezifana ne-COPD kunye nesifo sofuba se-pulmonary . Abaphandi baqhathanisa abafazi abangama-17 000 abangenayo umdlavuza wamaphaphu kunye nabesifazane abangaphezu kwe-17 000 abaye bafumana umdlavuza wamaphaphu phakathi kuka-2005 no-2010. Ukusetyenziswa kwexesha elide leZocor (simvastatin) kwakuhambelana nomngcipheko ongaphantsi kwe-20 yomhlaza wamaphaphu xa kuthelekiswa nabasetyhini abangazange basebenzise mayeza. Ukusetyenziswa kwexesha elide leMevacor (lovastatin), kodwa, kwakunxulumene nomngcipheko ophantsi wesi sifo.
Funda ngokuchasene kwangoko malunga nokusetyenziswa kweemimiselo kubasetyhini .
Yintoni Okufanele Uyenze Ngolu Lwazi?
Njengoko kuphawuliwe ngasentla, olu phando lusemncinci, kwaye iziphakamiso malunga nokusetyenziswa kwe-statin ngokukodwa kumhlaza awuzange kwenziwe. Kulabo basebenzise imishanguzo ye-statin ye-cholesterol ephakamileyo ngexesha lokunyangwa komhlaza wamaphaphu, ezi zifundo zingakhokelela. Ungathanda kwakhona ukuxubusha imeko yakho ethile kubandakanye iphrofayili yakho yeepidid kunye ne-oncologist yakho kwaye umbuze ukuba ucinga ntoni ngale nkcazelo.
Olu lwazi luza ngexesha apho izikhokelo zangaphambili kwi-cholesterol zibizwa ngokuba ngumbuzo. NgoDisemba ka-2014, umqulu oqulunqiweyo weKomiti yeeKhokelo zeZilathisi zeZondlo yathi i-cholesterol yokutya ayisabonwa njengomdla wokuxhalabisa. Oku kucacile ngesihloko esiya kudingwa ukuba sixoxwe kwaye sibe ngabanye phakathi kwakho kunye ne-oncologist yakho.
Amanyathelo alandelayo
Kukho izinto ezilula abantu abanokuzenza ngokwabo ukuphucula ukusinda nomhlaza wemiphunga. Hlola ezi zinto ezili-10 ezinokuphucula ukusinda kwakho kumdlavuza wamaphaphu .
Imithombo
IKadiwell, C, McMenamin, U., Hughes, C., noL. Murray. Ukusetyenziswa kweStatin kunye Nokusinda kwiChre Cancer: Isifundo soLuntu oluSebenziweyo. I-Epidemiology ye-Cancer Biomarkers kunye nokukhusela . 2015. 24 (5): 833-41.
UKen, J. et al. I-Atorvastatin inqoba i-gefitinib ukuxhatshazwa kwii-KRAS ezingezona zincinci zamaseli e-cell lung cellcinoma. Ukufa kunye neSifo . 2013 Septemba 26: 4: e814.
Cheng, M., Chiu, H., Ho. S., no-C. Yang. Ukusetyenziswa kweStatin kunye nomngcipheko wesifo somhlaza wamaphaphu: isifundo solawulo lwe-case-based based-population. Cancer Lung . 2012. 75 (3): 275-9.
Fiala, O., Pesek, M., Finek, J., Minarik, M., Benesova, L., Bortlicek, Z., kunye no-O. Topolcan. Izitatimende zandisa ukuphumelela kwee-EGFR-TKIs kwizigulane ezinomdla osemgangathweni ongeyomncinci wesifo somhlaza wamaphaphu ohlala kwi-KRAS. Biology Biology . 2015 Feb 22. (Epub ngaphambi kokuprinta)
Park, I., Kim, J., Jumg, J., noJan Han. I-Lovastatin inqoba ukunqandwa kwe-gefitinib kumaseli omhlaza wesifo somzimba womntu ongekho amancinci kunye noguquko lwe-K-Ras. Uphando olutsha lweeDrugs . 2010. 28 (6): 791-9.
Yang, T., Lin, W., Lin, C., Sung, F., kunye noCao. Ulungelelwano phakathi kokusetyenziswa kwe-simvastatin kunye ne-lovastatin kunye nomngcipheko wesifo somhlaza wamaphaphu: isifundo solawulo lwelizwe lonke. I-International Journal ye-Clinical Practice . 2015. 69 (5): 571-6.
Zhong, S., Zhang, X., Chen., L., Ma, T., Tang, J., noJ. Zhao. Ukusetyenziswa kweStatin kunye nokufa kwabantu kwizigulane zomhlaza: Ukuhlaziywa kwesistim kunye nokuhlaziywa kweemeta zophando. Uphononongo lweZonyango . 2015 Apr 11. (Epub ngaphambi kokushicilela)